Strong Q1 Performance: McKesson reported record consolidated revenues of $97.8 billion for the first quarter of Fiscal 2026, a 23% increase year-over-year. Adjusted operating profit grew 9% to $1.4 billion, with notable double-digit growth in three of its four segments, indicating strong operational execution and adherence to strategic growth commitments.

Raised Full-Year Guidance: The company increased its full-year earnings per diluted share guidance to a range of $37.10 to $37.90, up from $36.90 to $37.70. This adjustment reflects the strong start to the fiscal year, driven by the performance in the U.S. Pharmaceutical segment and confidence in ongoing growth across all segments.

Acquisition Strategy: McKesson has been active in expanding its capabilities through acquisitions, including PRISM Vision and Core Ventures, which are expected to contribute 6-7% to the fiscal 2026 operating profit growth in the U.S. Pharmaceutical segment. These acquisitions enhance their oncology and multi-specialty solutions, positioning the company for durable growth.